Company profile: Qrons
1.1 - Company Overview
Company description
- Provider of preclinical biotech solutions developing advanced cell-based therapies and proprietary synthetic hydrogels—injectable, 3D printable polypseudorotaxane hydrogels that inhibit harmful neuronal processes and promote regeneration—and nano tellurium-based compositions to treat infectious diseases, resistant bacteria, sepsis, and neuronal diseases.
Products and services
- Synthetic Hydrogels: Proprietary hydrogels serving as building blocks for products and treatments targeting neuronal and infectious diseases
- Tellurium Compositions: Nano-scale tellurium-based compounds engineered to treat infectious diseases caused by resistant bacteria, sepsis, and other neuronal diseases
- Therapeutic Polypseudorotaxane Hydrogels: A synthetic, soft, injectable, and 3D printable hydrogel that inhibits harmful processes in neuronal pathologies and promotes neuronal regeneration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Qrons
Oasmia
HQ: Sweden
Website
- Description: Provider of human and veterinary oncology drugs, developing, manufacturing, marketing and selling novel formulations of well-established cytostatics with improved properties, reduced side effects and expanded therapeutic use. Portfolio includes Paccal Vet (XR-17) for canine cancers, Cantrixil for blood cancer, Docetaxel micellar for prostate cancer, and XR-18 delivery technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oasmia company profile →
DiscoverX
HQ: United States
Website
- Description: Provider of reagents, complete cell-based assay kits, profiling and screening services, and other turn-key solutions for the drug discovery, screening, and life science markets, offering biochemical and cell-based assays to improve research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiscoverX company profile →
Culture Biosciences
HQ: United States
Website
- Description: Provider of cloud-connected bioreactors and Console software enabling remote, real-time design, monitoring, and analysis of cell culture and bioprocess experiments, plus bioprocess development services including clone screening, process characterization, media screening, and process optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Culture Biosciences company profile →
Precision NanoSystems
HQ: Canada
Website
- Description: Provider of tools and processes for developing and manufacturing nanoparticles for medicines and medical research, offering the NanoAssemblr benchtop instrument for nanoparticle prototyping and for developing nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics, and Neuro9Kit to study gene function in neurons and glia cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision NanoSystems company profile →
Nektar Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics based on an advanced polymer conjugate chemistry platform, including Rezpegaldesleukin (REZPEG/NKTR-358), a regulatory T cell stimulator targeting the IL-2 receptor complex to address immune imbalances in autoimmune and inflammatory diseases; PEG-CSF Protein to modulate inflammation resolution; and a bivalent TNFR antibody that selectively stimulates TNFR2 to enhance T regulatory cell function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nektar Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Qrons
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Qrons
2.2 - Growth funds investing in similar companies to Qrons
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Qrons
4.2 - Public trading comparable groups for Qrons
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →